Sorafenib, Carboplatin, and Paclitaxel in Treating Patients With Stage IV Melanoma of the Eye
Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well sorafenib works when given together with carboplatin
and paclitaxel in treating patients with stage IV melanoma of the eye. Drugs used in
chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth
of tumor cells, either by killing the cells or by stopping them from dividing. Sorafenib may
help carboplatin and paclitaxel work better by making tumor cells more sensitive to the
drugs. Sorafenib may also stop the growth of melanoma by blocking some of the enzymes needed
for tumor cell growth and by blocking blood flow to the tumor. Giving sorafenib together with
carboplatin and paclitaxel may kill more tumor cells.